Abstract
Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC50 = 6.33 ± 0.40 µM), 7 (IC50 = 22.0 ± 0.33 µM), 2 (IC50 = 23.1 ± 1.78 µM), 17 (IC50 = 23.9 ± 1.46 µM), and 3 (IC50 = 33.8 ± 1.61 µM) showed more potent β-glucuronidase inhibitory activity than the standard (D-saccharic acid 1,4 lactone, IC50 = 48.4 ± 1.25 µM). This study has identified a new series of potential β-glucuronidase inhibitors. A structure-activity relationship has also been studied.
Keywords: Benzimidazole, β-glucuronidase inhibition, glucuronosyl-O-bonds, antihelmintic, anticoagulant, leukaemia, antihistaminic, antihypertensive, dimethylformamide, lepromatous
Medicinal Chemistry
Title:Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives
Volume: 8 Issue: 3
Author(s): Khalid Mohammed Khan, Momin Khan, Nida Ambreen, Fazal Rahim, Shagufta Naureen, Shahnaz Perveen, M. Iqbal Choudhary and Wolfgang Voelter
Affiliation:
Keywords: Benzimidazole, β-glucuronidase inhibition, glucuronosyl-O-bonds, antihelmintic, anticoagulant, leukaemia, antihistaminic, antihypertensive, dimethylformamide, lepromatous
Abstract: Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC50 = 6.33 ± 0.40 µM), 7 (IC50 = 22.0 ± 0.33 µM), 2 (IC50 = 23.1 ± 1.78 µM), 17 (IC50 = 23.9 ± 1.46 µM), and 3 (IC50 = 33.8 ± 1.61 µM) showed more potent β-glucuronidase inhibitory activity than the standard (D-saccharic acid 1,4 lactone, IC50 = 48.4 ± 1.25 µM). This study has identified a new series of potential β-glucuronidase inhibitors. A structure-activity relationship has also been studied.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Khan Momin, Ambreen Nida, Rahim Fazal, Naureen Shagufta, Perveen Shahnaz, Iqbal Choudhary M. and Voelter Wolfgang, Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives, Medicinal Chemistry 2012; 8 (3) . https://dx.doi.org/10.2174/1573406411208030421
DOI https://dx.doi.org/10.2174/1573406411208030421 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
Current Cancer Drug Targets Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews Insights into the Biological Evaluation of Pterocarpanquinones and Carbapterocarpans with Anti-tumor Activity against MDR Leukemias
Anti-Cancer Agents in Medicinal Chemistry Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews